Cart summary

You have no items in your shopping cart.

Suplatast tosilate

SKU: orb1223578

Description

A Th2 cytokine inhibitor that attenuates IL-2, IL-5 and IL-13 production and has no effect on IFN-γ production; suppresses IgE production, eosinophil infiltration and histamine release; exhibits antiasthmatic, anti-inflammatory and antifibrotic activity in vivo and is orally active.Allergy Approved(In Vitro):IPD-1151T (1-10 μM; 10 d) induces a concentration-dependent suppression of purified allergen (Cry j 1)-dependent IgE synthesis in autologous B cell cultures mediated by SN-4, without significantly affecting the IgG synthesis.IPD-1151T (1-10 μM; 24 h) clearly depresses phytohemagglutinin (PHA)-induced expression of IL-4 mRNA in normal peripheral blood mononuclear cells (PBMC).(In Vivo):Suplatast Tosilate (100 mg/kg; once daily for 21 d) inhibits the production of Th2 cytokines, which inhibits eosinophil infiltration into the murine airway, IgE synthesis, and development of BHR, in a murine model of asthma.Suplatast Tosilate (100 μg/kg; once daily for 14 d) strongly suppresses immunoglobulin E contents in serum.

Images & Validation

Key Properties

CAS Number94055-76-2
MW499.6406
Purity>98% (HPLC)
FormulaC23H33NO7S2
SMILESCCOCC(O)COC1=CC=C(NC(=O)CC[S+](C)C)C=C1
TargetIL Receptor
SolubilityDMSO: ≥ 33 mg/mL

Bioactivity

In Vivo
Suplatast Tosilate (100 mg/kg; once daily for 21 d) inhibits the production of Th2 cytokines, which inhibits eosinophil infiltration into the murine airway, IgE synthesis, and development of BHR, in a murine model of asthma. Suplatast Tosilate (100 μg/kg; once daily for 14 d) strongly suppresses immunoglobulin E contents in serum. Animal model: Female BALB/c mice (6-8 weeks old) are immunized with ovalbumin. Dosage: 100 mg/kg. Administration: p.o. once a day for 21 days. Result: Reduced the number of total cells and eosinophils. Almost completely inhibited the development of antigen-induced bronchial hyperresponsiveness (BHR). Decreased the levels of IL-4, IL-5 and IL-13.
In Vitro
IPD-1151T (1-10 μM; 10 d) induces a concentration-dependent suppression of purified allergen (Cry j 1)-dependent IgE synthesis in autologous B cell cultures mediated by SN-4, without significantly affecting the IgG synthesis. IPD-1151T (1-10 μM; 24 h) clearly depresses phytohemagglutinin (PHA)-induced expression of IL-4 mRNA in normal peripheral blood mononuclear cells (PBMC).

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

IPD-1151T

Similar Products

  • Suplatast (Tosilate) [orb1310921]

    99.65%

    94055-76-2

    499.64

    C23H33NO7S2

    50 mg, 1 ml x 10 mM (in DMSO)
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

Suplatast tosilate (orb1223578)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

500 mg
50 mg
$ 80.00
100 mg
$ 110.00
200 mg
$ 150.00